HC Wainwright Reiterates “Buy” Rating for Sensei Biotherapeutics (NASDAQ:SNSE)

HC Wainwright restated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $4.00 price objective on the stock.

Sensei Biotherapeutics Trading Up 18.0 %

SNSE opened at $0.51 on Friday. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The stock has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.49. The stock has a market capitalization of $12.78 million, a P/E ratio of -0.43 and a beta of 0.16.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the quarter. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.